Annual CFI
-$390.30 K
-$60.90 K-18.49%
December 31, 2022
Summary
- As of February 21, 2025, NAVB annual cash flow from investing activities is -$390.30 thousand, with the most recent change of -$60.90 thousand (-18.49%) on December 31, 2022.
- During the last 3 years, NAVB annual CFI has fallen by -$1.16 million (-150.66%).
- NAVB annual CFI is now -101.44% below its all-time high of $27.16 million, reached on December 31, 2011.
Performance
NAVB Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$524.70 K
-$459.70 K-707.23%
September 30, 2023
Summary
- As of February 21, 2025, NAVB quarterly cash flow from investing activities is -$524.70 thousand, with the most recent change of -$459.70 thousand (-707.23%) on September 30, 2023.
- Over the past year, NAVB quarterly CFI has dropped by -$459.70 thousand (-707.23%).
- NAVB quarterly CFI is now -101.93% below its all-time high of $27.17 million, reached on September 30, 2011.
Performance
NAVB Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$701.10 K
-$445.80 K-174.62%
September 30, 2023
Summary
- As of February 21, 2025, NAVB TTM cash flow from investing activities is -$701.10 thousand, with the most recent change of -$445.80 thousand (-174.62%) on September 30, 2023.
- Over the past year, NAVB TTM CFI has dropped by -$445.80 thousand (-174.62%).
- NAVB TTM CFI is now -102.58% below its all-time high of $27.16 million, reached on December 31, 2011.
Performance
NAVB TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
NAVB Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -18.5% | -707.2% | -174.6% |
| 3 y3 years | -150.7% | -707.2% | -174.6% |
| 5 y5 years | +78.7% | -707.2% | -174.6% |
NAVB Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -18.5% | at low | -1231.7% | at low | -174.6% | at low |
| 5 y | 5-year | -150.7% | +5.5% | -1235.1% | at low | -191.0% | at low |
| alltime | all time | -101.4% | +97.6% | -101.9% | +94.2% | -102.6% | +95.7% |
Navidea Biopharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$524.70 K(+707.2%) | -$701.10 K(+174.6%) |
| Jun 2023 | - | -$65.00 K(+65.0%) | -$255.30 K(-18.0%) |
| Mar 2023 | - | -$39.40 K(-45.3%) | -$311.50 K(-20.2%) |
| Dec 2022 | -$390.30 K(+18.5%) | -$72.00 K(-8.7%) | -$390.30 K(-4.3%) |
| Sep 2022 | - | -$78.90 K(-34.9%) | -$407.70 K(-11.8%) |
| Jun 2022 | - | -$121.20 K(+2.5%) | -$462.00 K(+21.5%) |
| Mar 2022 | - | -$118.20 K(+32.2%) | -$380.10 K(+15.4%) |
| Dec 2021 | -$329.40 K(-20.2%) | -$89.40 K(-32.9%) | -$329.40 K(+2.1%) |
| Sep 2021 | - | -$133.20 K(+238.9%) | -$322.60 K(-18.5%) |
| Jun 2021 | - | -$39.30 K(-41.8%) | -$396.00 K(-4.8%) |
| Mar 2021 | - | -$67.50 K(-18.3%) | -$415.90 K(+0.8%) |
| Dec 2020 | -$412.80 K(-153.6%) | -$82.60 K(-60.0%) | -$412.80 K(+6.3%) |
| Sep 2020 | - | -$206.60 K(+249.0%) | -$388.20 K(-2050.8%) |
| Jun 2020 | - | -$59.20 K(-8.1%) | $19.90 K(-95.8%) |
| Mar 2020 | - | -$64.40 K(+11.0%) | $479.10 K(-37.8%) |
| Dec 2019 | $770.40 K(-19.2%) | -$58.00 K(-128.8%) | $770.40 K(-3.9%) |
| Sep 2019 | - | $201.50 K(-49.6%) | $801.50 K(+37.3%) |
| Jun 2019 | - | $400.00 K(+76.3%) | $583.80 K(-25.2%) |
| Mar 2019 | - | $226.90 K(-943.5%) | $780.60 K(-18.2%) |
| Dec 2018 | $953.80 K(-152.0%) | -$26.90 K(+66.0%) | $953.70 K(-19.1%) |
| Sep 2018 | - | -$16.20 K(-102.7%) | $1.18 M(+0.6%) |
| Jun 2018 | - | $596.80 K(+49.2%) | $1.17 M(-181.7%) |
| Mar 2018 | - | $400.00 K(+102.3%) | -$1.43 M(-21.8%) |
| Dec 2017 | -$1.83 M(+4577.8%) | $197.70 K(-952.2%) | -$1.83 M(-9.7%) |
| Sep 2017 | - | -$23.20 K(-98.8%) | -$2.03 M(+1.2%) |
| Jun 2017 | - | -$2.01 M(<-9900.0%) | -$2.01 M(+5269.5%) |
| Mar 2017 | - | $0.00(0.0%) | -$37.40 K(-4.6%) |
| Dec 2016 | -$39.20 K(+41.0%) | $0.00(0.0%) | -$39.20 K(-18.0%) |
| Sep 2016 | - | $0.00(-100.0%) | -$47.80 K(-3.8%) |
| Jun 2016 | - | -$37.40 K(+1977.8%) | -$49.70 K(+12.2%) |
| Mar 2016 | - | -$1800.00(-79.1%) | -$44.30 K(+59.4%) |
| Dec 2015 | -$27.80 K(-98.2%) | -$8600.00(+352.6%) | -$27.80 K(-41.5%) |
| Sep 2015 | - | -$1900.00(-94.1%) | -$47.50 K(-88.7%) |
| Jun 2015 | - | -$32.00 K(-317.7%) | -$419.70 K(-18.9%) |
| Mar 2015 | - | $14.70 K(-151.9%) | -$517.60 K(-66.1%) |
| Dec 2014 | -$1.52 M(+18.0%) | -$28.30 K(-92.4%) | -$1.52 M(-23.7%) |
| Sep 2014 | - | -$374.10 K(+188.0%) | -$2.00 M(+15.8%) |
| Jun 2014 | - | -$129.90 K(-86.9%) | -$1.73 M(-10.5%) |
| Mar 2014 | - | -$992.60 K(+98.0%) | -$1.93 M(+49.2%) |
| Dec 2013 | -$1.29 M(+92.4%) | -$501.20 K(+390.4%) | -$1.29 M(+54.0%) |
| Sep 2013 | - | -$102.20 K(-69.2%) | -$839.30 K(-14.6%) |
| Jun 2013 | - | -$332.10 K(-6.9%) | -$982.60 K(+10.8%) |
| Mar 2013 | - | -$356.90 K(+642.0%) | -$887.20 K(+32.1%) |
| Dec 2012 | -$671.80 K(-102.5%) | -$48.10 K(-80.4%) | -$671.70 K(+20.7%) |
| Sep 2012 | - | -$245.50 K(+3.7%) | -$556.60 K(-102.1%) |
| Jun 2012 | - | -$236.70 K(+67.4%) | $26.86 M(-0.8%) |
| Mar 2012 | - | -$141.40 K(-311.0%) | $27.08 M(-0.3%) |
| Dec 2011 | $27.16 M(-6911.7%) | $67.00 K(-99.8%) | $27.16 M(+0.4%) |
| Sep 2011 | - | $27.17 M(<-9900.0%) | $27.06 M(<-9900.0%) |
| Jun 2011 | - | -$22.10 K(-63.9%) | -$216.20 K(-39.4%) |
| Mar 2011 | - | -$61.30 K(+88.6%) | -$356.80 K(-10.5%) |
| Dec 2010 | -$398.70 K(-222.1%) | -$32.50 K(-67.6%) | -$398.80 K(+1.5%) |
| Sep 2010 | - | -$100.30 K(-38.4%) | -$393.10 K(+25.2%) |
| Jun 2010 | - | -$162.70 K(+57.5%) | -$314.10 K(+44.1%) |
| Mar 2010 | - | -$103.30 K(+285.4%) | -$217.90 K(-166.7%) |
| Dec 2009 | $326.60 K(-152.1%) | -$26.80 K(+25.8%) | $326.50 K(-300.4%) |
| Sep 2009 | - | -$21.30 K(-68.0%) | -$162.90 K(+4990.6%) |
| Jun 2009 | - | -$66.50 K(-115.1%) | -$3200.00(-98.1%) |
| Mar 2009 | - | $441.10 K(-185.5%) | -$170.40 K(-72.8%) |
| Dec 2008 | -$627.30 K | -$516.20 K(-473.0%) | -$627.40 K(+439.0%) |
| Sep 2008 | - | $138.40 K(-159.2%) | -$116.40 K(-55.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2008 | - | -$233.70 K(+1369.8%) | -$259.50 K(+658.8%) |
| Mar 2008 | - | -$15.90 K(+205.8%) | -$34.20 K(-28.6%) |
| Dec 2007 | -$48.00 K(-103.5%) | -$5200.00(+10.6%) | -$47.90 K(-60.0%) |
| Sep 2007 | - | -$4700.00(-44.0%) | -$119.70 K(-29.3%) |
| Jun 2007 | - | -$8400.00(-71.6%) | -$169.30 K(+39.5%) |
| Mar 2007 | - | -$29.60 K(-61.6%) | -$121.40 K(-108.9%) |
| Dec 2006 | $1.36 M(-183.6%) | -$77.00 K(+41.8%) | $1.36 M(-59.6%) |
| Sep 2006 | - | -$54.30 K(-237.5%) | $3.37 M(-18.9%) |
| Jun 2006 | - | $39.50 K(-97.3%) | $4.15 M(+23.9%) |
| Mar 2006 | - | $1.45 M(-24.8%) | $3.35 M(-306.1%) |
| Dec 2005 | -$1.63 M(+1369.1%) | $1.93 M(+164.3%) | -$1.63 M(-54.6%) |
| Sep 2005 | - | $730.90 K(-196.0%) | -$3.58 M(-17.5%) |
| Jun 2005 | - | -$761.70 K(-78.4%) | -$4.34 M(+20.2%) |
| Mar 2005 | - | -$3.53 M(>+9900.0%) | -$3.62 M(+3166.7%) |
| Dec 2004 | -$110.70 K(+1.1%) | -$26.30 K(-11.7%) | -$110.70 K(+0.7%) |
| Sep 2004 | - | -$29.80 K(-9.7%) | -$109.90 K(-17.1%) |
| Jun 2004 | - | -$33.00 K(+52.8%) | -$132.50 K(+17.6%) |
| Mar 2004 | - | -$21.60 K(-15.3%) | -$112.70 K(+2.9%) |
| Dec 2003 | -$109.50 K(-65.2%) | -$25.50 K(-51.3%) | -$109.50 K(-108.0%) |
| Sep 2003 | - | -$52.40 K(+297.0%) | $1.37 M(-34.6%) |
| Jun 2003 | - | -$13.20 K(-28.3%) | $2.10 M(-5.3%) |
| Mar 2003 | - | -$18.40 K(-101.3%) | $2.22 M(-803.9%) |
| Dec 2002 | -$314.70 K(-389.8%) | $1.46 M(+116.2%) | -$314.70 K(-80.3%) |
| Sep 2002 | - | $673.30 K(+542.5%) | -$1.60 M(-30.1%) |
| Jun 2002 | - | $104.80 K(-104.1%) | -$2.29 M(-5.5%) |
| Mar 2002 | - | -$2.55 M(-1572.2%) | -$2.42 M(-2329.9%) |
| Dec 2001 | $108.60 K(-92.3%) | $173.10 K(-1246.4%) | $108.50 K(-195.9%) |
| Sep 2001 | - | -$15.10 K(-47.9%) | -$113.10 K(-21.8%) |
| Jun 2001 | - | -$29.00 K(+41.5%) | -$144.60 K(+43.0%) |
| Mar 2001 | - | -$20.50 K(-57.7%) | -$101.10 K(-107.2%) |
| Dec 2000 | $1.40 M(+278.9%) | -$48.50 K(+4.1%) | $1.40 M(-3.3%) |
| Sep 2000 | - | -$46.60 K(-421.4%) | $1.45 M(-3.1%) |
| Jun 2000 | - | $14.50 K(-99.0%) | $1.50 M(+1.0%) |
| Mar 2000 | - | $1.48 M(>+9900.0%) | $1.48 M(-55.1%) |
| Dec 1999 | $369.90 K(-96.5%) | - | - |
| Jun 1999 | - | $0.00(-100.0%) | $3.30 M(-53.5%) |
| Mar 1999 | - | $400.00 K(+0.3%) | $7.10 M(-33.0%) |
| Dec 1998 | $10.60 M(+4199.8%) | $398.90 K(-84.0%) | $10.60 M(+50.4%) |
| Sep 1998 | - | $2.50 M(-34.2%) | $7.05 M(0.0%) |
| Jun 1998 | - | $3.80 M(-2.6%) | $7.05 M(+989.9%) |
| Mar 1998 | - | $3.90 M(-223.7%) | $646.50 K(+162.3%) |
| Dec 1997 | $246.50 K(-101.5%) | -$3.15 M(-226.1%) | $246.50 K(-107.7%) |
| Sep 1997 | - | $2.50 M(-196.2%) | -$3.20 M(-60.0%) |
| Jun 1997 | - | -$2.60 M(-174.3%) | -$8.00 M(-44.4%) |
| Mar 1997 | - | $3.50 M(-153.0%) | -$14.40 M(-11.1%) |
| Dec 1996 | -$16.20 M(+165.6%) | -$6.60 M(+187.0%) | -$16.20 M(+78.0%) |
| Sep 1996 | - | -$2.30 M(-74.4%) | -$9.10 M(-30.5%) |
| Jun 1996 | - | -$9.00 M(-629.4%) | -$13.10 M(+118.3%) |
| Mar 1996 | - | $1.70 M(+240.0%) | -$6.00 M(-1.6%) |
| Dec 1995 | -$6.10 M(0.0%) | $500.00 K(-107.9%) | -$6.10 M(-60.4%) |
| Sep 1995 | - | -$6.30 M(+231.6%) | -$15.40 M(+102.6%) |
| Jun 1995 | - | -$1.90 M(-218.8%) | -$7.60 M(+153.3%) |
| Mar 1995 | - | $1.60 M(-118.2%) | -$3.00 M(-50.8%) |
| Dec 1994 | -$6.10 M(+408.3%) | -$8.80 M(-686.7%) | -$6.10 M(-229.8%) |
| Sep 1994 | - | $1.50 M(-44.4%) | $4.70 M(-2.1%) |
| Jun 1994 | - | $2.70 M(-280.0%) | $4.80 M(+1100.0%) |
| Mar 1994 | - | -$1.50 M(-175.0%) | $400.00 K(-133.3%) |
| Dec 1993 | -$1.20 M(-66.7%) | $2.00 M(+25.0%) | -$1.20 M(-62.5%) |
| Sep 1993 | - | $1.60 M(-194.1%) | -$3.20 M(-33.3%) |
| Jun 1993 | - | -$1.70 M(-45.2%) | -$4.80 M(+54.8%) |
| Mar 1993 | - | -$3.10 M | -$3.10 M |
| Dec 1992 | -$3.60 M | - | - |
FAQ
- What is Navidea Biopharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals annual CFI year-on-year change?
- What is Navidea Biopharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals quarterly CFI year-on-year change?
- What is Navidea Biopharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals TTM CFI year-on-year change?
What is Navidea Biopharmaceuticals annual cash flow from investing activities?
The current annual CFI of NAVB is -$390.30 K
What is the all time high annual CFI for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high annual cash flow from investing activities is $27.16 M
What is Navidea Biopharmaceuticals annual CFI year-on-year change?
Over the past year, NAVB annual cash flow from investing activities has changed by -$60.90 K (-18.49%)
What is Navidea Biopharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of NAVB is -$524.70 K
What is the all time high quarterly CFI for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high quarterly cash flow from investing activities is $27.17 M
What is Navidea Biopharmaceuticals quarterly CFI year-on-year change?
Over the past year, NAVB quarterly cash flow from investing activities has changed by -$459.70 K (-707.23%)
What is Navidea Biopharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of NAVB is -$701.10 K
What is the all time high TTM CFI for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high TTM cash flow from investing activities is $27.16 M
What is Navidea Biopharmaceuticals TTM CFI year-on-year change?
Over the past year, NAVB TTM cash flow from investing activities has changed by -$445.80 K (-174.62%)